Seres Therapeutics earnings release, August 5, 2026

Seres Therapeutics, Inc. (MCRB) · Form 8-K, Item 2.02 · Filed · SEC filing

SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING

FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS

Recently announced 80% of

SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK)

IST data support

SER-155 as a potential treatment for irEC that may allow patients to continue cancer therapy; Company evaluating irEC clinical development strategy in consultation with KOLs

Seres engaging potential partners, seeking capital to advance its

SER-155 programs, including for the prevention of bloodstream infections in patients undergoing allo-HCT and those experiencing irEC

Seres announces agreement to exit additional leased space early, further reducing ongoing facility-related cash costs, which follows announcement of balance sheet strengthening and facilities cost reduction transactions in June 2026

CAMBRIDGE, Mass.- August 5, 2026 — Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported second quarter 2026 financial results and provided business updates.

“We are very pleased with the recent progress at Seres, including the positive topline data from the investigator-sponsored trial of

SER-155 in irEC conducted by MSK, announced last month,” said Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres. “The study demonstrated that 80% of participants achieved an immunosuppressive-free clinical response at day 15, and the accompanying pharmacology data reinforced that our live biotherapeutic operated as designed, including by repairing the mucosal epithelial barrier.

SER-155 to treat irEC, a frequent and often severe side effect of widely used immune checkpoint inhibitor (ICI) cancer treatment, represents a meaningful therapeutic and commercial opportunity, as many patients who experience irEC are required to halt their ICI therapy and begin immunosuppressive corticosteroid treatment. We are engaging potential partners, including companies with ICI franchises, as we evaluate the clinical development pathway in this indication and consider sources of financing. In parallel, we continue to pursue partnerships and other financing sources to support development of

SER-155 in allo-HCT, and to advance our broader inflammatory and immune portfolio, including

SER-603 for inflammatory bowel disease.”

Marella Thorell,

Chief Financial Officer of Seres, added, “Terminating our Sidney Street lease will substantially reduce our future lease obligations and will further lower our ongoing annual fixed costs beginning in 2027. Together with the lease restructuring we announced in June, this transaction reflects our continued focus on rigorous financial discipline, while we maintain the operational infrastructure needed to advance our live biotherapeutic pipeline, including our Phase

2-ready

SER-155 program in allo-HCT.”

Recent Highlights

SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC)

Broader pipeline and portfolio

Corporate Updates

Seres completed the below transactions that will collectively strengthen the Company’s balance sheet and reduce ongoing annual facility cash costs.

Second Quarter 2026 Financial Results

Cash and Cash Runway

As of June 30, 2026, Seres had $15.6 million in cash and cash equivalents. Based on Seres’ currently available cash resources, including the

$12.5 million Milestone Termination Payment received from Nestlé on July 1, 2026, and the expected receipt of the remaining $12.5 million Milestone Termination Payment from Nestlé on October 1, 2026, and considering future operating plans, the Company expects to fund operations through the first quarter of 2027. This projection excludes proceeds from any potential future partnerships or other sources of capital.

About Seres Therapeutics

Seres Therapeutics, Inc.

(Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products (LBP), designed to address unmet needs in oncology that can lead to interruption to patients’ cancer care and/or mortality, and to treat inflammatory and immune (I&I) diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to

Nestlé Health Science.

SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), and is Phase 2 ready, pending receipt of funding.

SER-155 is also being developed to address immune checkpoint inhibitor-related enterocolitis (irEC) to provide an immunosuppressive-free alternative and enable patients to continue their ICI cancer therapy. Having recently reported promising results from an IST, Seres is evaluating the design of a

Phase 2 study in irEC. The Company is advancing

IND-enabling studies for

SER-603, which is in development for inflammatory bowel disease. Mechanistically, Seres’ biotherapeutics target the mucosal epithelial barrier-immune interface and are optimized to modulate host function to increase mucosal epithelium integrity, induce immune homeostasis, and prevent the colonization and overgrowth of harmful bacteria in the GI tract. For more information, please visit www.serestherapeutics.com..rward-Looking Statements

Financial statements

Income Statement

Three Months Ended June 30, — (unaudited, in thousands, except share and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:Grant revenue7361,094
Revenue:Total revenue7361,094
Operating expenses:Research and development expenses9,14112,93922,33624,760
Operating expenses:General and administrative expenses7,06110,25315,13122,141
Operating expenses:Impairment of long-lived assets5,8075,807
Operating expenses:Manufacturing services1,6895,216
Operating expenses:Total operating expenses22,00924,88143,27452,117
Operating expenses:Loss from operations-21,273-24,881-42,180-52,117
Other income (expense):Gain on sale of VOWST Business25,00018525,00052,366
Other income (expense):Interest income1815465061,164
Other income (expense):Other income (expense) (1)6734,2951,34211,414
Other income (expense):Total other income (expense), net25,8545,02626,84864,944
Other income (expense):Net income (loss) and comprehensive income (loss)4,581-19,855-15,33212,827
Other income (expense):Net income (loss) per share attributable to common stockholders – basic0.47-2.27-1.591.47
Other income (expense):Net income (loss) per share attributable to common stockholders – diluted0.47-2.27-1.591.47
Other income (expense):Weighted average common shares outstanding – basic9,706,1938,743,7339,644,7048,723,589
Other income (expense):Weighted average common shares outstanding – diluted9,747,1388,743,7339,644,7048,732,176

Balance Sheet

December 31, — (unaudited, in thousands, except share and per share data)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents15,59445,766
Current assets:Accounts receivable due from SPN - related party25,000360
Current assets:Accounts receivable274157
Current assets:Prepaid expenses and other current assets1,4803,093
Current assets:Total current assets42,34849,376
Current assets:Property and equipment, net5,7987,635
Current assets:Operating lease assets51,16872,483
Current assets:Restricted cash2,2438,668
Current assets:Other non-current assets3131
Current assets:Total assets101,588138,193
Current liabilities:Accounts payable1,1861,682
Current liabilities:Accrued expenses and other current liabilities3,7393,972
Current liabilities:Accrued liabilities due to SPN - related party3,2783,278
Current liabilities:Operating lease liabilities11,82810,390
Current liabilities:Total current liabilities20,03119,322
Current liabilities:Operating lease liabilities, net of current portion44,81672,576
Current liabilities:Other long-term liabilities2,2072,077
Current liabilities:Total liabilities67,05493,975
Stockholders’ equity (deficit):Common stock, $0.001 par value; 360,000,000 shares authorized at June 30, 2026 and December 31, 2025; 9,827,569 and 9,556,466 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1010
Stockholders’ equity (deficit):Additional paid-in capital1,022,2591,016,611
Stockholders’ equity (deficit):Accumulated deficit-987,735-972,403
Stockholders’ equity (deficit):Total stockholders’ equity34,53444,218
Stockholders’ equity (deficit):Total liabilities and stockholders’ equity101,588138,193
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about:

SER-155 and its intended uses and benefits in irEC; our clinical development plans for

SER-155,

SER-603 and

SER-428; potential accessibility for patients; the timing and results of clinical studies and data readouts; current or future product candidates and their potential impacts and outcomes; engagement with potential partners and financing sources; our ability to access capital to advance our programs; expected receipt of milestone termination payments; our lease restructuring activities and anticipated cost savings and liability reductions; our cash runway; our planned strategic focus; the anticipated timing of any of the foregoing; and other statements that are not historical fact.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5) our limited operating history; (6) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company; (7) we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The Nasdaq Stock

Market LLC; (8) our novel approach to therapeutic intervention; (9) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (10) our ability to achieve market acceptance necessary for commercial success; (11) the competition we will face; (12) our ability to protect our intellectual property; (13) impact of our recent management transitions and appointments and our ability to retain key personnel; and

(14) disruptions at the FDA or other government agencies. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form

10-Q for the quarterly period ended June 30, 2026, to be filed with the Securities and Exchange Commission (SEC) on August 5, 2026, as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Seres Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.